Drugs News and Research

RSS

Existing drug mitigates muscle loss from GLP-1 medications

Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss.

2 Jun 2026

New funding supports cutting-edge research to combat cancers across South Texas

The University of Texas at San Antonio (UT San Antonio) and its academic health center, UT Health San Antonio, recently received over $2.7 million in new academic and prevention awards from the Cancer Prevention and Research Institute of Texas (CPRIT) to further its mission of combating cancers across South Texas.

2 Jun 2026

First-in-class cancer drug gamitrinib evaluated in phase 1 clinical trial

Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse."

2 Jun 2026

GLP-1 medications linked to lower breast cancer risk in women

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

2 Jun 2026

New discovery provides insights into how seasonal influenza viruses infect people

Scientists investigating how influenza viruses replicate within cells "accidentally" discovered that different flu viruses use distinct strategies to infiltrate cells in the first place.

2 Jun 2026

Southwest Research Institute evaluates NASA's medication handling practices

Southwest Research Institute evaluated NASA's medication handling practices, which currently call for removing medications from their original packaging and storing them in resealable plastic bags.

2 Jun 2026

Building quality into drug development for safer, faster medicines

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 2 Jun 2026

Advancing Human Muscle Models for Drug Development and Preclinical Testing

Transforming drug development, Myomaker Bio's lab-grown muscle platforms offer human-relevant models for effective preclinical testing and risk reduction.

From Myomaker Bio 2 Jun 2026

PromptSE AI predicts drug side effects by reasoning through biological clues

PromptSE uses structured LLM prompting to generate pharmacologically relevant side-effect representations, then feeds them into deep learning models to predict drug-side effect associations. In benchmark testing, PromptSE improved prediction performance, while PromptSE+ further boosted results by adding multi-modal drug information and graph-based refinement for sparse data.

1 Jun 2026

Brazilian study links TP53 mutations to poor lung cancer prognosis

Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as smoking and ethnicity.

1 Jun 2026

Weight loss drugs could widen health inequalities without nutritional support

Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according to researchers at UCL and the University of Cambridge.

1 Jun 2026

Health workers face hidden exposure to cancer-linked hazards

A study reveals high exposure to cancer risk factors among health and social care workers in Europe, underscoring the need for enhanced protective measures.

1 Jun 2026

Global policy gaps slow biosimilar adoption and access

Nine out of 10 prescriptions are filled by generic drugs - FDA-approved carbon copies of brand-name drugs with expired patents.

1 Jun 2026

New imaging method distinguishes inflammation from lung fibrosis

A new SPECT/CT imaging approach can accurately differentiate inflammation from fibrosis in interstitial lung disease (ILD) patients, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

1 Jun 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026

Teclistamab delivers deeper responses in relapsed myeloma patients

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

29 May 2026

Free contraception program sharply reduces patient spending in British Columbia

Researchers at UBC found that B.C.'s decision to provide universal, no-cost prescription contraception sharply reduced what patients pay, with the largest financial gains for people in their 20s.

29 May 2026

Review explores diagnosis and management of perioperative anaphylaxis during anesthesia

Perioperative anaphylaxis is a rare, life‑threatening condition during anesthesia. The unique setting – multiple drugs, patient draping, and altered physiology – causes higher mortality than anaphylaxis elsewhere.

29 May 2026

Novel therapeutic agent proposed to combat drug resistant tuberculosis

A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques.

29 May 2026